APONTIS PHARMA announces a successful 2021 exercise – Unique pills as a growth engine


DGAP-News: APONTIS PHARMA AG / Key word(s): Preliminary results/Annual results

APONTIS PHARMA announces a successful 2021 exercise – Unique pills as a growth engine

03.03.2022 / 07:30
The issuer is solely responsible for the content of this announcement.

APONTIS PHARMA announces a successful 2021 exercise – Unique pills as a growth engine

  • Single drug revenues increase significantly by 65% ​​to 31.5 million euros
  • Single pill revenue share increases to 62% (2020: 49%)
  • 270,000 patients treated with unique APONTIS PHARMA pills (2020: 174,000)
  • Total revenue rises sharply by 31% to 51.2 million euros according to preliminary calculations
  • EBITDA increases to €5.9 million before IPO costs (2020: €1.0 million)
  • EBITDA margin before IPO costs improves to 11.5% (2020: 2.6%)
  • Forecasts for 2022: growth in turnover to 55.3 million euros and EBITDA to 5.5 million euros
  • Medium-term objective of 100 million euros in revenue and 30% EBITDA margin by 2026 reaffirmed

Monheim am Rhein, March 3, 2022. APONTIS PHARMA AG (Symbol APP / IS IN DE000A3CMGM5), a leading pharmaceutical company specializing in monopills in the German market, recorded revenue growth of 31% to 51.2 million euros in fiscal year 2021, above initial forecasts and above the industry average, based on preliminary figures. Physicians’ growing acceptance of the proven single-pill therapy concept helped significantly exceed the projected revenue increase of €49.5 million (previously €48.5 million ). The new preparations Atorimib (cholesterolemic agent) and TonotecHCT (antihypertensive agent) and established single pills, such as Tonotec, recorded double-digit growth rates. In this context, APONTIS PHARMA has increased its share of voice with doctors thanks to the excellent commitment of its sales force during the corona pandemic. The number of patients under treatment with APONTIS PHARMA’s unique pills has increased by 55%.

According to preliminary calculations, Single Pills revenue increased significantly by 65% ​​to EUR 31.5 million in 2021 and contributed 62% to APONTIS PHARMA’s total revenue (2020: 49%) . The growth in turnover and the increase in the share of Single Pills thus exceeded the expectations of the Management Board. An anticipated build-up of stocks by wholesalers at the end of the year for the Caramlo product in response to bottlenecks among competitors led to a non-recurring positive effect of €0.5 million on sales. Earnings before interest, taxes, depreciation and amortization (EBITDA) were more than five times higher than the prior year figure (2020: €1.0 million) at €5.9 million before expenses. ‘Initial Public Offering. The forecast EBITDA of 5.5 million euros was largely exceeded. Before IPO costs, the EBITDA margin increased to 11.5% (2020: 2.6%). The Management Board of APONTIS PHARMA sees its medium-term planning confirmed, with the expansion of the portfolio to more than 20 Single Pills, in order to be able to achieve an EBITDA margin of approximately 30% on revenues of 100 million euros by 2026.

With an equity ratio of 75% as of December 31, 2021, cash and cash equivalents of 29.8 million euros and liabilities of only 3.7 million euros, APONTIS PHARMA has a financial situation and healthy financial position to finance its continued growth.

Unit pills will continue to be APONTIS PHARMA’s main growth driver in 2022. The Management Board expects three new product launches during the current financial year. These are expected to make a significant contribution to revenue from 2023 onwards. The Board of Directors expects revenue to increase to €55.3 million in fiscal year 2022. In order to be able to monetize more strongly the momentum of the publication of the START 2022 study on the superiority of single pills as a therapeutic concept in the treatment of chronic diseases sick patients in long-term therapy, management intends to invest more in marketing and sales measures in 2022 to ensure future growth. Consequently, the management board forecasts an EBITDA of 5.5 million euros in 2022.

Karlheinz Gast, Managing Director of APONTIS PHARMA AG: “During the first financial year since the IPO of APONTIS PHARMA in May 2021, we have achieved key milestones on the way to our medium-term growth objectives, as announced. In doing so, we accelerated the distribution and expansion of our own product portfolio and further expanded our market position in Germany as “The Single Pill Company”. The launches of two Single Pills announced in 2021 for the current fiscal year are signs of the continuation of our success story. We will now be launching at least three Single Pills this year. We are particularly proud of the launch of the development of a Single Pills. The START study, to which APONTIS PHARMA will hold the European rights for the first time, underlines the future growth potential of our Single Pills. Through targeted investments in marketing and sales, we intend to capitalize on this momentum and, alongside the expansion of our pipeline, we are now setting the course to achieve our ambitious targets of 100 million euros in revenue and an EBITDA margin of 2026. 30%.”

Group preliminary figures for 2021 (unaudited)

in millions of euros 2021 2020 ?
Single pill revenue 31.5 19.1 65.2%
Total revenue 51.2 39.2 30.6%
EBITDA before IPO costs 5.9 1.0 490.0%
EBITDA margin before IPO costs 11.5% 2.6% 342.3%
Equity ratio 75.3% 11.6% 549.1%
Cash and cash equivalents 29.8 8.1 267.9%

To note: Figures for fiscal year 2021 are unaudited and preliminary. Rounding differences may occur.

The complete 2021 annual report of APONTIS PHARMA AG will be available on the company’s website at ir.apontis-pharma.de as of March 30, 2022.


CEO Karlheinz Gast, CPO Thomas Milz and CFO Thomas Zimmermann will explain the results for the 2021 financial year during a webcast presentation today at 09:30 CET. The presentation will be in English.

Please register in time to participate in:

APONTIS PHARMA Preliminary results 2021 – Webcast/conference call

The accompanying presentation will also be available on the Company’s website prior to the start of the event.


APONTIS PHARMA AG is a leading pharmaceutical company specializing in unit pills in Germany. Individual pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of unique pills and other pharmaceutical products, with a particular focus on cardiovascular diseases. Since 2013, APONTIS has successfully launched several single pill products for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its head office in Monheim am Rhein, APONTIS PHARMA is established in one of the main pharmaceutical and chemical regions of Europe. From there, the company maintains an extensive network with research-oriented pharmaceutical companies and a customer target group of approx. 23,000 doctors in Germany. For more information about APONTIS PHARMA, please visit www.apontis-pharma.de.


Investor Relations
[email protected]
Phone. : +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. ten
40789 Monheim am Rhein


CROSS ALLIANCE communication GmbH
Sven Pauly
Sara Pinto
[email protected]
Phone. : +49 89 125 09 0330

03.03.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de


About Author

Comments are closed.